3,479 press releases in English indexed under healthcare.
Published in Critical Care Medicine, findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HENDERSON, Nev., Aug. 26, 2026 -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a...
NEEDHAM, Mass., Aug. 26, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026.
SEATTLE and RICHMOND, BC, Aug. 26, 2026 -- Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's...
MIAMI, Aug. 26, 2026 -- PharmaForceIQ has today introduced Optichannel 360, an AI-native commercial execution platform that connects field and digital marketing, including a new measurement answer-to-action workflow. The Optichannel 360 platform is built as a broader...
NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31, 2026 in Munich, Germany.
HOUSTON, Aug. 26, 2026 -- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:
FORM 8.3
U.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection
Key opportunities include software, mixed reality and healthcare applications, especially immersive medical training. Growth potential also lies in integrated spatial data, digital workspace and location-aware platforms, with expansion in Asia Pacific and the Middle East. Key opportunities include software, mixed reality and healthcare applications, especially immersive medical training. Growth potential also lies in integrated spatial data, digital workspace and location-aware platforms, with expansion in Asia Pacific and the Middle East.
Expanding clinical pipelines and outsourcing are boosting CDMO demand. Opportunities include scalable cell/vector production, non-viral platforms, automation and faster analytics. Expanding clinical pipelines and outsourcing are boosting CDMO demand. Opportunities include scalable cell/vector production, non-viral platforms, automation and faster analytics.
LONDON, August 26, 2026--VirTus Respiratory Research Ltd, a specialist respiratory contract research organisation (CRO), founded by Imperial College London investigators Professor Sebastian Johnston and Dr Michael Edwards, today highlighted its role in the preclinical development of Apollo Therapeutics’ and Imperial’s APL-10456, following the announcement of positive initial data from the vaccine’s Phase 1 clinical trial.
Tokyo, Japan and Cambridge, UK, 26 August 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner Neurocrine Biosciences Inc. (“Neurocrine”) has received IND Acceptance from the U.S. Food and Drug Administration (FDA) for a Phase 2 study of NBI-1117567 (“NBI-’567”) for Alzheimer's cognition. Nxera will receive an IND Acceptance milestone payment of US$10 million from Neurocrine pursuant to the agreement. The milestone payment is expected to be recognised in full as revenue in Q3 FY2026. NBI-’567 is an investigational, orally administered, muscarinic M1 receptor preferring agonist discovered using Nxera’s proprietary NxWave™ drug discovery platform.